American Society of Hematology

Figure 5

Antitumor efficacy of 131I-BC8 (anti-CD45) in a human T-NHL xenograft model. Tumor volume (A) and progression-free survival (B) in mice bearing human T-NHL xenografts (CCRF-CEM) after no treatment, BHV1 labeled with 300 μCi 131I (control), BC8 labeled with 300 μCi 131I, or BC8 labeled with 400 μCi 131I.

Antitumor efficacy of ¹³¹I-BC8 (anti-CD45) in a human T-NHL xenograft model. Tumor volume (A) and progression-free survival (B) in mice bearing human T-NHL xenografts (CCRF-CEM) after no treatment, BHV1 labeled with 300 μCi ¹³¹I (control), BC8 labeled with 300 μCi ¹³¹I, or BC8 labeled with 400 μCi ¹³¹I.

This Feature Is Available To Subscribers Only